BiotechTube

Dinutuximab + NK Cells + Lenalidomide

Phase 1Active
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroblastoma

Conditions

Neuroblastoma

Trial Timeline

Jan 14, 2019 → Dec 1, 2026

NCT ID
NCT02573896

About Dinutuximab + NK Cells + Lenalidomide

Dinutuximab + NK Cells + Lenalidomide is a phase 1 stage product being developed by United Therapeutics for Neuroblastoma. The current trial status is active. This product is registered under clinical trial identifier NCT02573896. Target conditions include Neuroblastoma.

What happened to similar drugs?

0 of 1 similar drugs in Neuroblastoma were approved

Approved (0) Terminated (0) Active (1)
🔄18F-MFBGIlluminaPhase 3

Hype Score Breakdown

Clinical
6
Activity
12
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02573896Phase 1Active

Competing Products

20 competing products in Neuroblastoma

See all competitors
ProductCompanyStageHype Score
LY3295668 Erbumine + Topotecan + CyclophosphamideEli LillyPhase 1
33
ZD6474 + Retinoic AcidAstraZenecaPhase 1
21
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acidAstraZenecaPhase 2
35
PRRT with 177Lu-DOTATATENovartisPhase 1
36
Topotecan + Temozolomide + RibociclibNovartisPhase 1
21
Topotecan hydrochlorideNovartisPhase 2
35
Ribociclib + CeritinibNovartisPhase 1
21
Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + CyclophosphamideRochePhase 2
39
GPC2 CAR T cellsGilead SciencesPhase 1
36
lorlatinibPfizerPre-clinical
18
Lorlatinib + Cyclophosphamide + Topotecan + Filgrastim/pegfilgrastimPfizerPhase 1
29
Nifurtimox + Cyclophosphamide + TopotecanBayerPhase 2
32
DinutuximabUnited TherapeuticsPre-clinical
15
Dinutuximab with ChemotherapyUnited TherapeuticsPhase 1
30
ch14.18 -NCI + ch14.18-UTC + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) + Aldesleukin (IL-2) + IsotretinoinUnited TherapeuticsPhase 1/2
29
Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + TemsirolimusUnited TherapeuticsPhase 2
32
MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic AcidUnited TherapeuticsPhase 2
24
Radiation: 131I-MIBG + Dinutuximab + VorinostatUnited TherapeuticsPhase 2
39
Dinutuximab + Vorinostat + Sargramostim + Potassium IodideUnited TherapeuticsPhase 1
26
Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSFUnited TherapeuticsPhase 2
39